Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study

Summary - Background - Routine prophylactic platelet transfusion is the standard of care for patients with severe thrombocytopenia. We assessed the effect of a new strategy of therapeutic platelet transfusion on the number of transfusions and safety in patients with hypoproliferative thrombocytopeni...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Wandt, Hannes (VerfasserIn) , Thalheimer, Markus (VerfasserIn) , Mahlknecht, Ulrich Rudolph (VerfasserIn) , Ho, Anthony Dick (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: August 7, 2012
In: The lancet
Year: 2012, Jahrgang: 380, Heft: 9850, Pages: 1309-1316
ISSN:1474-547X
DOI:10.1016/S0140-6736(12)60689-8
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1016/S0140-6736(12)60689-8
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0140673612606898
Volltext
Verfasserangaben:Hannes Wandt, Kerstin Schaefer-Eckart, Knut Wendelin, Bettina Pilz, Martin Wilhelm, Markus Thalheimer, Ulrich Mahlknecht, Anthony Ho, Markus Schaich, Michael Kramer, Martin Kaufmann, Lothar Leimer, Rainer Schwerdtfeger, Roland Conradi, Gottfried Dölken, Anne Klenner, Mathias Hänel, Regina Herbst, Christian Junghanss, Gerhard Ehninger

MARC

LEADER 00000caa a2200000 c 4500
001 158764942X
003 DE-627
005 20220815103337.0
007 cr uuu---uuuuu
008 190214s2012 xx |||||o 00| ||eng c
024 7 |a 10.1016/S0140-6736(12)60689-8  |2 doi 
035 |a (DE-627)158764942X 
035 |a (DE-576)51764942X 
035 |a (DE-599)BSZ51764942X 
035 |a (OCoLC)1341037777 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Wandt, Hannes  |e VerfasserIn  |0 (DE-588)1178026329  |0 (DE-627)1049109023  |0 (DE-576)517648636  |4 aut 
245 1 0 |a Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies  |b an open-label, multicentre, randomised study  |c Hannes Wandt, Kerstin Schaefer-Eckart, Knut Wendelin, Bettina Pilz, Martin Wilhelm, Markus Thalheimer, Ulrich Mahlknecht, Anthony Ho, Markus Schaich, Michael Kramer, Martin Kaufmann, Lothar Leimer, Rainer Schwerdtfeger, Roland Conradi, Gottfried Dölken, Anne Klenner, Mathias Hänel, Regina Herbst, Christian Junghanss, Gerhard Ehninger 
264 1 |c August 7, 2012 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 14.02.2019 
520 |a Summary - Background - Routine prophylactic platelet transfusion is the standard of care for patients with severe thrombocytopenia. We assessed the effect of a new strategy of therapeutic platelet transfusion on the number of transfusions and safety in patients with hypoproliferative thrombocytopenia. - Methods - We did a multicentre, open-label, randomised parallel-group trial at eight haematology centres in Germany. Patients aged 16-80 years, who were undergoing intensive chemotherapy for acute myeloid leukaemia or autologous haemopoietic stem-cell transplantation for haematological cancers, were randomly assigned via a computer-generated randomisation sequence to receive either platelet transfusion when bleeding occurred (therapeutic strategy) or when morning platelet counts were 10×109 per L or lower (prophylactic strategy). Investigators undertaking interventions were not masked to group assignment. The primary endpoint was the number of platelet transfusions. Analysis was by intention to treat. This trial is registered, NCT00521664. - Findings - 197 patients were assigned the prophylactic strategy and 199 the therapeutic strategy. Of 391 patients analysed, the therapeutic strategy reduced the mean number of platelet transfusions by 33·5% (95% CI 22·2-43·1; p<0·0001) in all patients (2·44 [2·22-2·67] in prophylactic group vs 1·63 [1·42-1·83] in therapeutic group), 31·6% (18·6-42·6; p<0·0001) in those with acute myeloid leukaemia (2·68 [2·35-3·01] vs 1·83 [1·58-2·10]), and 34·2% (6·6-53·7; p=0·0193) in those who had had autologous transplantation (1·80 [1·45-2·15] vs 1·18 [0·82-1·55]. We noted no increased risk of major haemorrhage in patients who had undergone autologous transplantation. In those with acute myeloid leukaemia, risk of non-fatal grade 4 (mostly CNS) bleeding was increased. We recorded 15 cases of non-fatal haemorrhage: four retinal in each transfusion group, and one vaginal and six cerebral in the therapeutic group. 12 patients died in the study: two from fatal cerebral haemorrhages in the therapeutic group, and ten (five in each treatment group) unrelated to major bleeding. - Interpretation - The therapeutic strategy could become a new standard of care after autologous stem-cell transplantation; however, prophylactic platelet transfusion should remain the standard for patients with acute myeloid leukaemia. The new strategy should be used by some haematology centres only if the staff are well educated and experienced in the new approach and can react in a timely way to first signs of CNS bleeding. - Funding - Deutsche Krebshilfe eV (German Cancer Aid). 
700 1 |a Thalheimer, Markus  |d 1966-  |e VerfasserIn  |0 (DE-588)120743019  |0 (DE-627)080863078  |0 (DE-576)292363753  |4 aut 
700 1 |a Mahlknecht, Ulrich Rudolph  |d 1967-  |e VerfasserIn  |0 (DE-588)114964890  |0 (DE-627)568995538  |0 (DE-576)289814464  |4 aut 
700 1 |a Ho, Anthony Dick  |d 1948-  |e VerfasserIn  |0 (DE-588)108692477  |0 (DE-627)504904205  |0 (DE-576)19010466X  |4 aut 
773 0 8 |i Enthalten in  |t The lancet  |d London [u.a.] : Elsevier, 1823  |g 380(2012), 9850, Seite 1309-1316  |h Online-Ressource  |w (DE-627)270128484  |w (DE-600)1476593-7  |w (DE-576)078590159  |x 1474-547X  |7 nnas  |a Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies an open-label, multicentre, randomised study 
773 1 8 |g volume:380  |g year:2012  |g number:9850  |g pages:1309-1316  |g extent:8  |a Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies an open-label, multicentre, randomised study 
856 4 0 |u http://dx.doi.org/10.1016/S0140-6736(12)60689-8  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S0140673612606898  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190214 
993 |a Article 
994 |a 2012 
998 |g 108692477  |a Ho, Anthony Dick  |m 108692477:Ho, Anthony Dick  |d 910000  |d 910100  |e 910000PH108692477  |e 910100PH108692477  |k 0/910000/  |k 1/910000/910100/  |p 8 
998 |g 114964890  |a Mahlknecht, Ulrich Rudolph  |m 114964890:Mahlknecht, Ulrich Rudolph  |d 910000  |d 910100  |e 910000PM114964890  |e 910100PM114964890  |k 0/910000/  |k 1/910000/910100/  |p 7 
998 |g 120743019  |a Thalheimer, Markus  |m 120743019:Thalheimer, Markus  |d 50000  |e 50000PT120743019  |k 0/50000/  |p 6 
999 |a KXP-PPN158764942X  |e 3055909526 
BIB |a Y 
SER |a journal 
JSO |a {"physDesc":[{"extent":"8 S."}],"id":{"eki":["158764942X"],"doi":["10.1016/S0140-6736(12)60689-8"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 14.02.2019"],"relHost":[{"title":[{"title_sort":"lancet","title":"The lancet"}],"origin":[{"dateIssuedKey":"1823","publisherPlace":"London [u.a.] ; London","publisher":"Elsevier ; The Lancet Ltd.","dateIssuedDisp":"1823-"}],"part":{"volume":"380","text":"380(2012), 9850, Seite 1309-1316","pages":"1309-1316","year":"2012","issue":"9850","extent":"8"},"id":{"zdb":["1476593-7"],"issn":["1474-547X"],"eki":["270128484"]},"physDesc":[{"extent":"Online-Ressource"}],"titleAlt":[{"title":"The lancet <London>"},{"title":"London lancet"},{"title":"Lancet (British ed. Online)"}],"language":["eng"],"recId":"270128484","disp":"Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies an open-label, multicentre, randomised studyThe lancet","type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.1823 -"]}],"person":[{"role":"aut","family":"Wandt","display":"Wandt, Hannes","given":"Hannes"},{"role":"aut","family":"Thalheimer","display":"Thalheimer, Markus","given":"Markus"},{"given":"Ulrich Rudolph","display":"Mahlknecht, Ulrich Rudolph","family":"Mahlknecht","role":"aut"},{"role":"aut","family":"Ho","display":"Ho, Anthony Dick","given":"Anthony Dick"}],"name":{"displayForm":["Hannes Wandt, Kerstin Schaefer-Eckart, Knut Wendelin, Bettina Pilz, Martin Wilhelm, Markus Thalheimer, Ulrich Mahlknecht, Anthony Ho, Markus Schaich, Michael Kramer, Martin Kaufmann, Lothar Leimer, Rainer Schwerdtfeger, Roland Conradi, Gottfried Dölken, Anne Klenner, Mathias Hänel, Regina Herbst, Christian Junghanss, Gerhard Ehninger"]},"origin":[{"dateIssuedDisp":"August 7, 2012","dateIssuedKey":"2012"}],"recId":"158764942X","title":[{"subtitle":"an open-label, multicentre, randomised study","title_sort":"Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies","title":"Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies"}],"language":["eng"]} 
SRT |a WANDTHANNETHERAPEUTI7201